Wave Life Sciences Announces First-Ever Therapeutic RNA Editing …
2 days ago · GSK has the exclusive global license for WVE-006. Development and commercialization responsibilities will transfer to GSK after Wave completes the RestorAATion-2 study. In total, Wave is eligible for up to $525 million in milestones, as well as tiered royalties on net sales, for WVE-006. About Wave Life Sciences
Wave Life Sciences: Positive WVE-006 Data For AATD Leads To …
1 day ago · Wave Life Sciences' WVE-006 study shows significant promise in treating alpha-1 antitrypsin deficiency. Learn more about WVE stock's potential in this $10B market.
WVE Stock Soars on Upbeat Initial Antitrypsin Deficiency Study Data
17 hours ago · In consideration for the license grant, WVE is eligible to receive up to $525 million in milestone payments, as well as tiered royalties on net sales, from GSK, for WVE-006. WVE News Sparks a ...
Wave Clinical Trial Shows First Successful RNA Editing in Humans
1 day ago · WVE-006 is a GalNAc-conjugated, subcutaneously delivered, A-to-I RNA editing oligonucleotide (AIMer) intended to treat AATD-related lung disease, liver disease, or both. ... News of the human RNA ...
Wave stock soars 73% on positive data for RNA editing treatment …
1 day ago · Wave's WVE-006 news also stoked shares of two other RNA editing companies, Korro Bio and ProQR Therapeutics . Korro ( KRRO ) shares soared 114% in afternoon trading while ProQR ( PRQR ) shares ...
Wave Life soars on positive early data for WVE-006
22 hours ago · US RNA medicines biotech Wave Life Sciences yesterday announced positive proof-of-mechanism data from the ongoing Phase Ib/IIa RestorAATion-2 study of WVE-006 in alpha-1 antitrypsin deficiency (AATD), with the news sending the firm’s shares rocketing 71% to $11.24. WVE-006 is a GalNAc-conjugated, subcutaneously delivered, A-to-I RNA editing oligonucleotide (AIMer) that was developed with ...
Wave Life Sciences Announces Approval of First Clinical Trial ...
Apr 30, 2024 · WVE-006 is a first-in-class, GalNAc-conjugated and subcutaneously administered RNA editing oligonucleotide designed to correct the single base mutation in messenger RNA (mRNA) coded by the SERPINA1 Z allele, thereby enabling restoration and circulation of functional M-AAT protein.
Promising Potential of WVE-006 in RNA Editing: Andrew Fein’s …
1 day ago · In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Wave Life Sciences (WVE – Research Report), with a price target of $22.00. Andrew Fein has given his Buy ...
Wave hails human RNA editing first for GSK-partnered prospect
1 day ago · The update on the GSK-partnered prospect sent Wave’s share price up 63% to almost $14 despite coinciding with news that Takeda has ... Wave will wrap up the current study of WVE-006 and then ...
Positive Outlook for Wave Life Sciences Driven by Promising RNA …
1 day ago · The single 200mg doses of WVE-006 achieved a mean total AAT protein level close to 11uM, which is considered a potential regulatory threshold, with more than 60% being wild-type protein.
- Some results have been removed